Dermatology

Rheumatoid Arthritis

Questions discussed in this category

How do you approach managing nausea and GI side effects when initiating methotrexate?

Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?

Patient with chronic urticaria and rheumatoid arthritis. What would be the safest biologic option for RA?

How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?

Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?

1 Answer available

Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?

1 Answer available

How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?

Patient has had previous failure of methotrexate. Would you switch to alternative (TNFi or Rituximab) or continue abatacept with regular dermatology...

2 Answers available

Would you consider adding dupilumab to adalimumab (or other monoclonal antibodies) in a patient who has RA and refractory atopic dermatitis and already is on MTX 25 mg weekly?

2 Answers available

Have you used jak inhibitors with TNF blockade at the same time?

1 Answer available

How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?

In what cases do you discontinue the medication?

2 Answers available

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

2 Answers available

Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?

1 Answer available

What is your methotrexate initiation strategy in DMARD-naive RA patients?

Specifically: starting dose, rapidity of up-titration, frequency of lab monitoring, frequency of office visits, and timing of assessment for treatment...

2 Answers available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

2 Answers available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?